Back to Search
Start Over
T-cell-replete haploidentical transplantation in acute myeloid leukemia.
- Source :
-
Experimental hematology [Exp Hematol] 2018 Feb; Vol. 58, pp. 5-16. Date of Electronic Publication: 2017 Nov 17. - Publication Year :
- 2018
-
Abstract
- In the last decade, the number of haploidentical stem cell transplantation has increased because of the widespread use of T-cell-replete platforms developed worldwide. Acute myeloid leukemia (AML) is the main indication to perform allogeneic stem cell transplantation. Here, we reviewed the clinical results obtained using T-cell-replete platforms in different clinical situations such as first or further complete remission, refractory disease, and in the elderly population. Overall, the toxic profile of T-cell-replete haploidentical transplantation is similar to transplantation from other donors, with positive aspects such as a reduced incidence of chronic graft-versus-host disease. Leukemia-free survival and overall survival are also similar. In conclusion, T-cell-replete haploidentical transplantation represents a new frontier in the treatment landscape of AML, lessening problems linked to donor search and ensuring that a donor can be found for all patients in a timely manner.<br /> (Copyright © 2018 ISEH – Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1873-2399
- Volume :
- 58
- Database :
- MEDLINE
- Journal :
- Experimental hematology
- Publication Type :
- Academic Journal
- Accession number :
- 29155271
- Full Text :
- https://doi.org/10.1016/j.exphem.2017.11.001